RCS - Allergy Therapeutics - Allergy Therapeutics shares data at WAO-BSACI

Allergy TherapeuticsAnnouncement

25/04/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220425:nRSY1309Ja&default-theme=true

RNS Number : 1309J  Allergy Therapeutics PLC  25 April 2022

 

Allergy Therapeutics plc

("Allergy Therapeutics", the "Group" or "Company")

 

Allergy Therapeutics shares positive data at the 2022 WAO-BSACI Conference

 

25 April 2022 Allergy Therapeutics plc (AIM: AGY), the fully integrated
commercial biotechnology company specialising in allergy vaccines, will share
positive new data from across its research portfolio at the joint WAO (World
Allergy Organisation) & BSACI (British Society for Allergy & Clinical
Immunology) 2022 UK Conference in Edinburgh, Scotland, from 25 to 27 April
2022.

 

Potential novel grass pollen immunotherapy

The first of the Group's posters presents findings from the exploratory field
study (G309) conducted to further optimise the trial design of the upcoming
pivotal Phase III clinical trial (G306) investigating the Group's wholly owned
short-course grass pollen immunotherapy candidate, Grass MATA MPL. Data from
the study, conducted in the US and EU, show that the immunotherapy
demonstrated clinically relevant and statistically significant reductions in
the daily symptoms and the use of relief medications after 6 subcutaneous
allergen-specific immunotherapy (SCIT) injections in two different treatment
regimens. The results highlight the potential of this novel, short-course
immunotherapy targeting grass pollen allergies and support the route to
registration in both Europe and the US.

 

Real-World-Evidence data of MCT®-associated allergoid SCIT platform

Another poster reports on the Group's TARGET study. Real-World-Evidence data
are becoming increasingly important for academia but also regulators.
Real-World-Evidence allow insights into the therapeutic effectiveness of a
drug but also disease modification and or long-term effectiveness of allergen
immunotherapy (AIT). The aim of the "Tyrosine Allergoid Real World Evidence in
Germany Effectiveness in AIT" (TARGET) study was to demonstrate the long-term
benefit of MCT(®)-associated allergoid SCIT in routine clinical practice. The
progression of allergic rhinitis (AR) and asthma was measured in patients
receiving one of three allergoid SCIT in comparison to matched control groups
without AIT using prescription data of more than 181,000 German patients
within the statutory health insurance system based on the IMS(®) LRx database
(IQVIA, Germany). The TARGET study demonstrated long-term benefits of
allergoid SCIT including MCT®-associated allergoids on AR and asthma up to
9.5 years (Ø 6.3 years) of follow up in routine clinical practice.

 

The hypo-allergic potential of VLP Peanut against peanut exposure

The latest pre-clinical mechanistic data on Allergy Therapeutics' peanut
vaccine candidate, VLP Peanut, will also be showcased in a poster which
illustrates how a vaccine incorporating the major peanut allergen (recombinant
Ara h 2) has the potential to protect against all peanut allergens. The mouse
anaphylaxis model of peanut allergy demonstrated that the vaccine candidate
exhibited a non-reactogenic profile after intravenous challenge with whole
peanut extract. This result further supports the hypo-allergic potential of
VLP Peanut, in alignment with the results previously demonstrated using human
blood cells, which is a vital quality in delivering a viable peanut allergy
vaccine. Additional data being presented show that a single dose of VLP Peanut
protected mice against anaphylaxis in a peanut sensitized mouse model. The
upcoming Phase I PROTECT trial, the first human study exploring the potential
of this peanut vaccine candidate will begin later in 2022, following FDA
clearance of the Group's IND application, with topline data expected in 2023.

 

The posters will be presented at the WAO & BSACI UK Conference on Tuesday
26 April between 11:05 - 14:00 (BST) https://wao-bsaci.org/
(https://wao-bsaci.org/) . Abstracts of each will be made available on the
Company website.

 

- ENDS -

 

 

 

 

For further information, please contact:

 

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Chief Financial Officer

 

Panmure Gordon

+44 (0) 20 7886 2500

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

 

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott / David Daley / Davide Salvi

allergytherapeutics@consilium-comms.com
(mailto:allergytherapeutics@consilium-comms.com)

 

Stern Investor Relations, Inc.

+1 212 362 1200

Christina Tartaglia

christina@sternir.com (mailto:christina@sternir.com)

 

 

Notes for editors:

 

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company
focussed on the treatment and diagnosis of allergic disorders, including
aluminium free immunotherapy vaccines that have the potential to cure disease.
The Group sells proprietary and third-party products from its subsidiaries in
nine major European countries and via distribution agreements in an additional
ten countries. Its broad pipeline of products in clinical development includes
vaccines for grass, tree and house dust mite, and peanut allergy vaccine in
pre-clinical development. Adjuvant systems to boost performance of vaccines
outside allergy are also in development.

 

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is
headquartered in Worthing, UK with more than 11,000m(2) of state-of-the-art
MHRA-approved manufacturing facilities and laboratories. The Group employs
c.600 employees and is listed on the London Stock Exchange (AIM:AGY). For more
information, please see www.allergytherapeutics.com
(http://www.allergytherapeutics.com) .

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAKZLFLLZLZBBZ